Tepezza Hearing Loss Lawsuits 2026: What Thyroid Eye Disease Patients Should Know
Tepezza — the first FDA-approved treatment for thyroid eye disease — faces a federal mass-tort litigation over claims it can cause permanent hearing loss and tinnitus. Hundreds of cases sit in a Chicago multidistrict litigation, and in 2026 the central question is whether patients who lost hearing after infusions can prove the drug, not aging or illness, is responsible.
Key Facts
- The FDA approved Tepezza (teprotumumab) in January 2020 for thyroid eye disease, but a warning about potentially permanent hearing loss was not added to its label until 2023.
- In June 2023, the Judicial Panel on Multidistrict Litigation created an MDL in the Northern District of Illinois before Judge Thomas M. Durkin, consolidating federal hearing-loss cases.
- As of October 1, 2026, the JPML listed 279 pending cases in the MDL, with new filings still arriving.
- Bellwether test trials were initially scheduled for 2026, but in October 2025 the court removed all trial dates from the schedule, leaving the timetable uncertain.
- Plaintiffs allege Horizon Therapeutics failed to warn doctors and patients about permanent hearing damage and downplayed how often hearing complications occurred.
What the Lawsuits Claim About Tepezza
The core allegation is failure to warn. Patients say they received the standard course — typically eight infusions over about five months — without being told hearing loss or tinnitus was a meaningful risk, and that the company knew of early clinical signals and growing post-marketing reports long before the 2023 label change. An MDL does not decide every case at once: it coordinates discovery, expert testimony, and bellwether trials for the federal cases, so common questions about the drug's risks and the adequacy of warnings are answered efficiently. Bellwether outcomes typically shape settlement discussions across the remaining cases.
The Science Behind the Hearing-Loss Claims
Thyroid eye disease is an autoimmune condition — usually tied to Graves' disease — in which the immune system attacks tissues behind the eyes. Tepezza blocks IGF-1R, a receptor in that autoimmune process; plaintiffs' experts argue the same pathway is involved in the inner ear, giving a plausible mechanism for ototoxicity. Studies have reported hearing-related adverse events in a notable share of treated patients, and courts will weigh expert testimony on whether the pattern shows causation. The practical lesson for patients: get a baseline hearing test before starting Tepezza and report any ringing, muffling, or hearing change immediately. Documented before-and-after audiograms are the most persuasive evidence in these cases.
Who Benefits From This — and Who Does Not
Those most likely to benefit: Patients who developed persistent hearing loss or tinnitus after Tepezza infusions — especially those with pre-treatment audiograms showing normal hearing — hold the clearest claims. Patients whose doctors never warned them of auditory risks fit the failure-to-warn theory at the MDL's heart, and those treated before the 2023 label change can argue the warning came too late for them.
Those who do not benefit: People who took Tepezza with no hearing symptoms have no injury to claim — mass torts compensate harm, not risk. Claims are weak where hearing loss predates the infusions or has a clear alternate cause. And statutes of limitations vary by state and can quietly expire; waiting for the MDL to resolve before acting can cost you the claim. Readers comparing drug-injury mass torts can study similar warning-label fights in our guides to the Abilify lawsuits and the FDA warning and the Benicar litigation that ended in a $300 million settlement.
Where the MDL Stands in 2026
As of October 2026, the litigation is active but unscheduled. Four bellwether trials had been set for April, June, July, and September of 2026 — then, after an off-the-record discussion between the judge and both sides in October 2025, every trial date was removed, with a status hearing set to discuss case management. No new public trial dates have followed. The delay does not mean the cases are failing: hundreds of claims remain open and expert discovery has proceeded. For plaintiffs it cuts both ways — more time to build records, but no near-term verdict pressure on the defendant.
Frequently Asked Questions
Who benefits most from filing a Tepezza lawsuit?
Patients who developed persistent hearing loss or tinnitus after infusions — particularly with pre-treatment hearing tests showing the damage is new and treatment that occurred before the 2023 label warning.
Who should not file a Tepezza claim?
Do not file if you took Tepezza with no hearing problems — there is no injury. Claims are also weak where hearing loss predates treatment or has a clear alternate cause, or where your state's statute of limitations has run.
How do I start a Tepezza hearing-loss claim?
See an audiologist for formal hearing testing, gather your Tepezza records (infusion dates, prescribing physician, pharmacy records), write a dated timeline of symptom onset, and consult a product-liability attorney experienced with the MDL — most evaluate these cases without upfront cost.
Is there a Tepezza settlement yet?
No court-approved global settlement exists as of late 2026. Compensation in any future resolution would vary widely by case — severity and permanence of damage, quality of medical proof, timing of treatment — and most mass-tort settlements are confidential.
What must I prove to win?
That you took Tepezza, suffered hearing loss or tinnitus afterward, and that the drug caused it — supported by medical records, expert testimony on ototoxicity, and evidence the warnings were inadequate when you were treated.
Should I stop taking Tepezza because of the lawsuits?
Never stop a prescribed treatment based on litigation news. Tepezza remains an approved, effective therapy, and hearing effects do not occur in every patient. Discuss risks — including baseline and monitoring hearing tests — with your prescribing doctor.
For video explainers of pharmaceutical litigation, see the Problem Solved channel.
This article is for general information only and is not legal or medical advice. Consult a qualified attorney and your physician about your specific situation.